Cronos GroupCRON +3.06%86 FCF Yield % is 2.46 as of Jul. 01, 2026. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.54 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,003 Drug Manufacturers companies, Cronos Group ranks better than 62.31% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cronos Group FCF Yield % Related Terms
Cronos Group FCF Yield % Historical Data
* Premium members only.
The historical data trend for Cronos Group's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cronos Group's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (CRON) has a FCF Yield % of 2.46 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #378 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is Cronos Group's FCF Yield % too high?
Cronos Group's current FCF Yield % is 2.46. The Drug Manufacturers industry median FCF Yield % is 0.67. Cronos Group's value of 2.46 is 267.2% above this industry median. Based on the distribution chart, Cronos Group ranks #378 out of 1003 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #378 out of 1003 companies for FCF Yield %. This puts Cronos Group in the upper half of its industry. The industry median FCF Yield % is 0.67. Cronos Group's value of 2.46 is 267.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current FCF Yield % of 2.46 is 267.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current FCF Yield % is 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.54, compared to a current price of $2.87 — trading 19.1% below its estimated fair value. The current FCF Yield % is 2.46 and 267.2% above the Drug Manufacturers industry median of 0.67. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cronos Group (CRON), the current FCF Yield % is 2.46 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.87 is trading 19.1% below its estimated GF Value™ of $3.54.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
FCF Yield %: 2.46
GF Value™: $3.54 vs. price of $2.87 (19.1% below fair value)
Industry Position: 267.2% above the Drug Manufacturers median (#378 of 1003)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
